Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.12.4987

Associations of Serum Isoflavone, Adiponectin and Insulin Levels with Risk for Epithelial Ovarian Cancer: Results of a Case-control Study  

Otokozawa, Seiko (Department of Public Health, Sapporo Medical University School of Health Sciences)
Tanaka, Ryoichi (Department of Obstetrics and Gynecology, Sapporo Medical University School of Health Sciences)
Akasaka, Hiroshi (Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Health Sciences)
Ito, Eiki (Department of Obstetrics and Gynecology, Sapporo Medical University School of Health Sciences)
Asakura, Sumiyo (Department of Public Health, Sapporo Medical University School of Health Sciences)
Ohnishi, Hirofumi (Department of Public Health, Sapporo Medical University School of Health Sciences)
Saito, Shigeyuki (Department of Nursing, Sapporo Medical University School of Health Sciences)
Miura, Tetsuji (Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Health Sciences)
Saito, Tsuyoshi (Department of Obstetrics and Gynecology, Sapporo Medical University School of Health Sciences)
Mori, Mitsuru (Department of Public Health, Sapporo Medical University School of Health Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.12, 2015 , pp. 4987-4991 More about this Journal
Abstract
Background: The aim of this study was to examine the association of serum isoflavones, adiponectin, and insulin levels with ovarian cancer risk. Materials and Methods: We gathered cases with histologically confirmed epithelial ovarian cancer at Sapporo Medical University Hospital from October 2010 to September 2012. Potential controls were recruited from female inpatients without any history of cancer or diabetes mellitus in different wards of the same hospital over the same period of time. Serum isoflavones, adiponectin, and insulin levels were measured in order to estimate associations with ovarian cancer risk in a case-control study. Data from 71 cases and 80 controls were analyzed with a logistic regression model adjusting for known risk factors. Results: A significant reduction in ovarian cancer risk was observed for the high tertile of serum daidzein level versus the low ($P_{trend}<0.001$). A significant reduction in ovarian cancer risk was also observed for the high tertile of serum glycitein level versus the low ($P_{trend}=0.005$). Furthermore, a significant reduction in ovarian cancer risk was observed for the high tertile of serum adiponectin level versus the low ($P_{trend}=0.004$). Conversely, serum insulin level showed significantly elevated risk for ovarian cancer with the high tertile versus the low $P_{trend}<0.001$). Conclusions: Decreased serum isoflavones levels, such as those for daidzein and glycitein, decreased serum adiponectin levels, and increased serum insulin levels could be shown to be associated with elevated risk of ovarian cancer.
Keywords
Case-control study; isoflavones; insulin; adiponectin;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Ayyildiz T, Dolar E, Ugras N, et al, (2014). Association of adiponectin receptor (Adipo-R1/R2) expression and colorectal cancer. Asian Pacific J Cancer Prev, 15, 9385-90.   DOI
2 Brokaw J, Katsaros D, Wiley A, et al (2007). IGF-1 in epithelial ovarian cancer and its role in disease progression. Growth Factors, 25, 346-54.   DOI
3 Chang ET, Lee VS, Canchola AJ, et al (2007). Diet and risk of ovarian cancer in the california teachers study cohort. Am J Epidemiol, 165, 802-13.   DOI
4 Collaborative Group on Epidemiological Studies of Ovarian cancer, Bera V, Doll R, et al (2008). Ovarian cancer and oral contraceptives; collaborative reanalysis of data from 45epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet, 371, 303-14.   DOI
5 Coppola D, Saunders B, Fu L, et al (2007). The insulin -like growth factor 1 receptor transformation and tumorigenicity of ovarian mesothelial cells and down-regulates their Fas -receptor expression. Cancer Res, 59, 3264-70.
6 Dupont J, Reverchon M, Cloix L, et al (2012). Involvement of adipokines, AMPK, PI3K and the PPAR signaling pathways in ovarian follicle development and cancer. Int J Dev Biol, 56, 959-67.   DOI
7 Fantuzzi G (2005). Adipose tissue, adipokines, and inflammations. J Allergy Clin Immunol, 115, 911-9.   DOI
8 Giovannucci E (1995). Insulin and colon cancer. Cancer Causes Control, 6, 164-79.   DOI
9 Gossner G, Choi M, Tan L, et al (2007). Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells. Gynecol Oncol, 105, 23-30.   DOI
10 Gulcelik MA, Colakoglu K, Dincer H, et al (2012). Association between adiponectin and two different cancers; breast and colon. Asian Pac J Cancer Prev, 13, 395-8.   DOI   ScienceOn
11 Horn-Ross PL, John EM, Canchola AJ, et al (2003). Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst, 95, 1158-64.   DOI
12 Lihn AS, Pedersen SB, Richelsen B (2005). Adiponectin; action, regulation and association to insulin sensitivity. Obes Rev, 6, 13-21.   DOI
13 Kaaks R, Toniolo P, Akhmedkhanov A, et al (2000). Serum C-peptide, insulin -like growth factor (IGF)-1, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst, 92, 1592-600.   DOI
14 Lee AH, Su D, Pasalich M, et al (2014). Soy and isoflavone intake associated with reduced risk of ovarian cancer in southern Chinese women. Nutr Res, 34, 302-7.   DOI
15 Lee MM, Gomez SL, Chang JS, et al (2003). Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev, 12, 665-8.
16 Luhn P, Fallal CM, Weiss JM, et al (2013). Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev, 22, 1304-12.   DOI
17 Lukanova A, Lundin, Toniolo P, et al (2002). Circulating levels of insulin-like growth -1 and risk of ovarian cancer. Int J Cancer, 101, 549-54.   DOI
18 Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.   DOI
19 Piver MS, Goldberg JM, Tsukada Y, et al (1996). Characteristics of familial ovarian cancer; a report of the first 1,000 Families in the Gilda Rander Familial ovarian cancer registry. Eur J Gynaecol Oncol, 17, 169-76.
20 Qu X-L, Fang Y, Zhang M, Zhang Y-Z (2014). Phytoestrogen intake and risk of ovarian cancer; a meta-analysis of 10 observational studies. Asian Pac J Cancer Prev, 15, 9085-91.   DOI
21 Rossi M, Negri E, Lagiou P, et al (2008). Flavonoids and ovarian cancer risk; A case-control study in Italy. Int J Cancer, 123, 895-8.   DOI
22 Risch A, Marrett LD, Jain M, et al (1996).Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol, 144, 363-72.   DOI
23 Rizzuto I, Behrens RF, Smith LA (2013). Risk of ovarian cancer in women treated ovarian stimulating drugs for infertility. Cochrane Database Syst Rev, 8.
24 Roberts DL, Dive C, Renehan AG (2010). Biological mechanisms liking obesity and cancer risk; new perspectives. Annu Rev Med, 61, 301-16.   DOI   ScienceOn
25 Rufer CE, Glatt H, Kulling SK (2006). Structural elucidation of hydroxylated metabolites of the isoflavone equol by gas chromatogtaphy-mass spectrometry and high-performance liquid chromatography -mass spectrometry. Drug Metab Dispos, 34, 51-60.
26 Schoen RE, Tangen CM, Kuller LH, et al (1999). Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst, 91, 1147-54.   DOI
27 Soslow RA (2008). Histologic subtypes of ovarian carcinoma; an overview. Int J Gynecol Patho, 127, 161-74.
28 Troisi R, Potischman N, Hoover RN, et al (1997). Insulin and endometrial cancer. Am J Epidemiol, 146, 476-82.   DOI
29 Valladares M, Corsini G, Romero C (2014). Association between obesity and ovarian cancer. Rev Med Chil, 142, 593-8.   DOI
30 Wang XL, Hur HG, Lee JH, et al (2005). Enantioselective synthesis of S equol from dihydro- daidzein by a newly isolated anaerobic human intestinal bacterium. Appl Environ Microbiol, 71, 214-9.   DOI
31 Zhang M, Xie X, Lee AH, et al (2004). Soy and isoflavone intake are associated with reduced risk of ovarian cancer in Southeast China. Nutr Cancer, 49, 125-30.   DOI
32 Yamamoto S, Sobue T, Kobayashi M, et al (2003). Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst, 95, 906-13.   DOI